Welcome to LookChem.com Sign In|Join Free

CAS

  • or

54-71-7

Post Buying Request

54-71-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

54-71-7 Usage

Description

It is a bioactive chemical usually used as pharmaceutical agents such as acetylcholine receptor agonist, antiglaucoma agent, moitic, and sialogogue. Specifically, due to its desirable activity as acetylcholine receptor agonist, this chemical has been introduced to regulate muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice.1 Moreover, because of its good antiglaucoma effect, this substance is applied in a timolol plus maximum-tolerated antiglaucoma therapy.2 In addition, this chemical has been demonstrated to show a favourable miotic activity when incorporated into polymer capsules.3 Besides, this compound can be utilized to relieve the xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies.4

Reference

Li, B.; Duysen, E. G.; Volpicelli-Daley, L. A.; Levey, A. I.; Lockridge, O., Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice. Pharmacol. Biochem. Behav. 2003, 74, 977-986. Zimmerman, T. J.; Gillespie, J. E.; Kass, M. A.; Yablonski, M. E.; Becker, B., TIMOLOL PLUS MAXIMUM-TOLERATED ANTI-GLAUCOMA THERAPY. Arch. Ophthalmol. 1979, 97, 278-279. V Vidmar; S Pepeljnjak; Jalsenjak, I., The in vivo evaluation of poly(lactic acid) microcapsules of pilocarpine hydrochloride. Journal of Microencapsulation 1985, 2, 289-292. Nagler, R. M.; Nagler, A., Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant. 1999, 23, 1007-1011.

Chemical Properties

Crystalline Solid

Originator

Andre Carpine, Andre Laboratries Pvt. Ltd., India

Uses

Different sources of media describe the Uses of 54-71-7 differently. You can refer to the following data:
1. Antiglaucoma agent; miotic; sialogogue.
2. Acetylcholine receptor agonist
3. (+)-Pilocarpine hydrochloride is a muscarinic M1 and M2 acetylcholine receptor agonist with pKB values of 5 and 3.7, respectively. Systemic administration of (+)-Pilocarpine hydrochloride is typically used as an animal model for temporal lobe epilepsy and can mimic the generation of complex partial seizures by producing changes in hippocampal neuron morphology, membrane properties, and synaptic responses.

Manufacturing Process

The 1-methylimidazole-5-aldehyde is easily accessible from sarcosine methyl ester hydrochloride and dimethylamino-2-azaprop-2-en-1 Pilocarpine ylidenedimethylammonium.0.14 mol of ethyl diethylphosphonoethoxyacetate is slowly added dropwise with stirring and under inert gas to a suspension of 0.14 mol of NaH (paraffinfree) in 250 ml of abs. THF, the mixture is stirred for 1 h at 20°C and a solution of 0.093 mol of 1-methylimidazole-5-aldehyde in 100 ml of abs. THF is added dropwise. After stirring at 20°C for 10 min, the solvent is distilled off in vacuo, the residue is taken up in a little H2O, and the solution is acidified with 1 N HCl and washed several times with ether. The aqueous phase is rendered alkaline using 2 N NaOH with cooling (0°-5°C) and extracted several times with CH2Cl2. After drying of the organic extracts with Na2SO4, the solvent is removed in vacuo and 2-ethoxy-3-[(1-methyl-1H-imidazol-5yl)methyl]-acrilic acid ethyl ester. Yield: 99% of theory.122 ml of 45% diisobutylaluminum hydride solution (328 mmol) are slowly added dropwise under inert gas, with stirring and ice cooling, to a solution of 137 mmol of 2-ethoxy-3-[(1-methyl-1H-imidazol-5-yl)methyl]-acrilic acid ethyl ester in 600 ml of abs. C6H6. Stirring of the mixture is continued for a further 30 min at 0°-5°C and 600 ml of CH3OH, then 100 ml of H2O, are slowly added. The hydroxide precipitate is filtered off with suction and washed several times with hot CH3OH. After drying of the combined filtrates the solvents are distilled off in vacuo and the residue is crystallized using C2H5OH. 2-ethoxy-3-[(1-methyl-1H-imidazol-5-yl)methyl]-prop-2-en-1-ol was obtained. Yield: 100% of theory. The crude product is pure enough for the subsequent reaction. Recrystallization of an analytical sample from CH3OH/acetone: melting point 129°C.A solution of 58 mmol of 2-ethoxy-3-[(1-methyl-1H-imidazol-5-yl)methyl]prop-2-en-1-ol in 116.6 ml of HCl (= 116.6 mmol) is stirred at 30°-35°C for 1.5 h and concentrated in vacuo at the same temperature. The residual HCl is removed by distillation with CHCl3 in vacuo. After seeding, the residue crystallizes at 20°C (15 h) 1-hydroxy-3-[(1-methyl-1H-imidazol-5-yl)methyl]propan-2-one hydrochloride. The crystallizate is filtered off with suction, washed with a little CH3OH and dried in vacuo. Yield: 86% of theory; melting point 190°C.About 80-90% of the equivalent amount of NaOCH3 solution in CH3OH is slowly added dropwise at 20°C with stirring and exclusion of moisture to a suspension of 21.24 mmol of 1-hydroxy-3-[(1-methyl-1H-imidazol-5yl)methyl]-propan-2-one hydrochloride in 80 ml of CH3OH, in the course of which the pH of 6.5 is not to be exceeded. The solvent is distilled off in vacuo at a maximum of 30°C and the residue of 1-hydroxy-3-[(1-methyl-1Himidazol-5-yl)methyl]-propan-2-one is purified by flash chromatography (silica gel; CHCl3/CH3OH). Yield: 100% of theory; viscous, orange-colored oil.Catalytic amounts of 4-dimethylaminopyridine and a solution of 21.3 mmol of 1-hydroxy-3-[(1-methyl-1H-imidazol-5-yl)methyl]-propan-2-one in 80 ml of CH2Cl2 are added to a solution of 26.44 mmol of 2-diethylphosphonobutyric acid in 40 ml of purified CH2Cl2. After cooling to 0°-5°C, a solution of 23.5 mmol of dicyclohexylcarbodiimide in 60 ml of CH2Cl2 is added dropwise and the mixture is stirred for 1 h at 0°-5°C and for 2 h at 20°C. The crystallizeddicyclohexylurea is filtered off with suction and the filtrate is washed with H2O and saturated NaHCO3 solution. After drying of the organic phase the solvent is distilled off at 30°C in vacuo and the residue of 2-diethoxy-phosphoryl)butyric acid 3-[(1-methyl-1H-imidazol-5-yl)methyl]-2-oxo-propyl ester is purified by flash chromatography (silica gel; ethyl acetate/CH3OH). Yield: 95% of theory of a viscous, orange-colored oil.A mixture of 5 mmol each of 80% NaH and 15-crown-5 in 50 ml of absol. toluene is stirred at 20°C under inert gas for 10 min and a solution of 5 mmol of 2-diethoxy-phosphoryl)-butiric acid 3-[(1-methyl-1H-imidazol-5-yl)methyl]2-oxo-propyl ester in 50 ml of absol. toluene is then added dropwise. Stirring is continued for a further 15 min under inert gas and the mixture is hydrolyzed with a little water until phase separation is detectable. After separating off the organic phase, the aqueous layer is saturated with NaCl and extracted several times with CHCl3. The combined organic phases are the solvent is distilled off at 40°C in vacuo and the residue 3-ethyl-4-[(1-methyl1H-imidazol-5-yl)methyl]-5H-furan-2-one is purified twice by flash chromatography (silica gel; ethyl acetate/CH3OH). Yield: 52% of theory; virtually colorless oil.1.36 mmol of 3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]-5H-furan-2-one in 15.5 ml of CH3OH are hydrogenated for 5 h at 50 bar and 60°C using 210 mg of Pd/carbon (10%). After filtering off the catalyst and distilling off the solvent at 30°C in vacuo, the oily residue (about 250 mg) is treated with 10 ml of 1 N HCl and the mixture is stirred for 3 h at 20°C. The hydrochloric acid is distilled off in vacuo at 35°-40°C, the oily residue is taken up in a little CH3OH and ether is added. The precipitate of pilocarpine hydrochloride is recrystallized from CH3OH/ether. Yield: 73% of theory; melting point 210°C.

Brand name

Pilopine (Alcon); Salagen (Millot Laboratories, France).

Therapeutic Function

Cholinergic

General Description

Pilocarpine monohydrochlorideis the hydrochloride of an alkaloid obtainedfrom the dried leaflets of Pilocarpus jaborandi or P. microphyllus,in which it occurs to the extent of about 0.5% togetherwith other alkaloids.

Biochem/physiol Actions

Pilocarpine is alkaloid isolated from the shrub Pilocarpus species. It comprises imidazole ring and γ- lactone rings?in its structure. It has cholinergic potential and it stimulates the parasympathetic system. Pilocarpine is also effective for treating glaucoma. It stimulates ciliary muscle contraction by binding to muscarinic M3 receptors. It is effective in treating corneal dryness in Sjogren′s syndrome. It is a secretagogue, which improves salivary secretions in Xerostomia or a dry mouth condition in Sjogren′s syndrome patients and in radiotherapy patients with head and neck carcinoma.

Clinical Use

Pilocarpine, the salt of an alkaloid obtained from Pilocarpus jaborandi, is an example of a muscarinic agonist that does not adhere to the traditional SAR. In 1876, Langley reported that extracts containing the alkaloid stimulated the end organs of parasympathetic neurons. The structure of pilocarpine was reported in 1901. Pilocarpine is marketed as tablets (Salogen), an ophthalmic solution, and gel. It penetrates the eye well and is the miotic of choice for open-angle glaucoma and to terminate acute angle closure attacks. It also is used for the treatment of xerostomia (dryness of the mouth) caused by radiation therapy of the head and neck, Sjogren's syndrome, or as a side effect of some psychotropic drugs.

Safety Profile

Poison by ingestion, intraperitoneal, and intravenous routes. Experimental teratogenic and reproductive effects. Human systemic effects: cardiac changes. When heated to decomposition it emits very toxic fumes of HCl and NOx. See also PILOCARPINE.

Veterinary Drugs and Treatments

Pilocarpine is a miotic agent that is rarely used in the treatment of canine primary glaucoma. Pilocarpine causes the ciliary body muscle to constrict placing posteriorly directed tension on the base of the iris to mechanically pull open the iridocorneal angle structures. By causing miosis, it may prevent closure of the iridocorneal angle by preventing excess iris tissue from peripherally compromising the outflow of aqueous humor. Pilocarpine has also been used for diagnostic localization of parasympathetic denervation of the iris sphincter caused by lesions or trauma to Cranial Nerve III. The popularity of treatment of KCS with ophthalmic cyclosporine and tacrolimus has been associated with a decline in the use of pilocarpine for this disease; however, pilocarpine is still used orally as the primary treatment of neurogenic keratoconjunctivitis sicca in dogs as this condition does not respond to cyclosporine or tacrolimus.

Check Digit Verification of cas no

The CAS Registry Mumber 54-71-7 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 4 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 54-71:
(4*5)+(3*4)+(2*7)+(1*1)=47
47 % 10 = 7
So 54-71-7 is a valid CAS Registry Number.
InChI:InChI=1/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1

54-71-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • USP

  • (1538902)  Pilocarpinehydrochloride  United States Pharmacopeia (USP) Reference Standard

  • 54-71-7

  • 1538902-200MG

  • 4,588.74CNY

  • Detail

54-71-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (+)-Pilocarpine hydrochloride

1.2 Other means of identification

Product number -
Other names (3S,4R)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:54-71-7 SDS

54-71-7Synthetic route

(2S,3RS)-2-ethyl-3-(1-methyl-1H-imidazol-5-yl)butane-1,4-dioic acid 4-methyl ester

(2S,3RS)-2-ethyl-3-(1-methyl-1H-imidazol-5-yl)butane-1,4-dioic acid 4-methyl ester

pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

Conditions
ConditionsYield
With hydrogenchloride; sodium tetrahydroborate 1a.) iPrOH, -5 deg C, 1 h, 1b.) RT, 21 h, 2.) MeOH, water, 2 h; Yield given. Multistep reaction;
(3S,4RS,5RS)-3-ethyl-4-(methoxycarbonyl)-5-(1-methyl-1H-imidazol-5-yl)dihydro-2(3H)-furanone

(3S,4RS,5RS)-3-ethyl-4-(methoxycarbonyl)-5-(1-methyl-1H-imidazol-5-yl)dihydro-2(3H)-furanone

pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 100 percent / H2 / Pd/C (5percent) / methanol / 60 h / 3102.9 Torr
2: 1.) NaBH4, 2.) conc. aq. HCl / 1a.) iPrOH, -5 deg C, 1 h, 1b.) RT, 21 h, 2.) MeOH, water, 2 h
View Scheme
(2S,3R)-2-ethyl-3-(methoxycarbonyl)4-(1-methylimidazol-5-yl)-butyricacid

(2S,3R)-2-ethyl-3-(methoxycarbonyl)4-(1-methylimidazol-5-yl)-butyricacid

pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

Conditions
ConditionsYield
With lithium borohydride; sodium hydrogencarbonate In hydrogenchloride; methanol; water; isopropyl alcohol
(R)-3-ethylidene-4-[(1-methylimidazol-5-yl)methyl]tetrahydrofuran-2-one
1192231-13-2

(R)-3-ethylidene-4-[(1-methylimidazol-5-yl)methyl]tetrahydrofuran-2-one

pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

Conditions
ConditionsYield
Stage #1: (R)-3-ethylidene-4-[(1-methylimidazol-5-yl)methyl]tetrahydrofuran-2-one With platinum(IV) oxide; hydrogen In methanol at 20℃; for 24h;
Stage #2: With hydrogenchloride In ethanol; water at 0℃; Cooling;
cobalt(II) chloride hexahydrate

cobalt(II) chloride hexahydrate

pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

dichloro-bis(κN-(+)-pilocarpine)cobalt(II)

dichloro-bis(κN-(+)-pilocarpine)cobalt(II)

Conditions
ConditionsYield
With Na2CO3 In ethanol; water; ethyl acetate organic ligand in water alkalinized with Na2CO3 to pH=9; extracted with ethyl acetate; overlayered with 0.5 equivalent CoCl2*6H2O in EtOH; allowed to evaporate slowly at room temp. for 2 days; elem. anal.;97%
all cis-5,8,11,14,17-eicosapentaenoic acid
10417-94-4

all cis-5,8,11,14,17-eicosapentaenoic acid

pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

5-(((3R,4S)-4-ethyl-5-oxotetrahydrofuran-3-yl)methyl)-1-methyl-1H-imidazol-1-ium (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

5-(((3R,4S)-4-ethyl-5-oxotetrahydrofuran-3-yl)methyl)-1-methyl-1H-imidazol-1-ium (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

Conditions
ConditionsYield
Stage #1: pilocarpine hydrochloride With sodium hydrogencarbonate In methanol for 0.0833333h;
Stage #2: all cis-5,8,11,14,17-eicosapentaenoic acid In methanol at 20℃; for 16h;
96.8%
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(R)-1,2-dithiolane-3-pentanoic acid
1200-22-2

(R)-1,2-dithiolane-3-pentanoic acid

5-(((3R,4S)-4-ethyl-5-oxotetrahydrofuran-3-yl)methyl)-1-methyl-1H-imidazol-1-ium (R)-5-(1,2-dithiolan-3-yl)pentanoate

5-(((3R,4S)-4-ethyl-5-oxotetrahydrofuran-3-yl)methyl)-1-methyl-1H-imidazol-1-ium (R)-5-(1,2-dithiolan-3-yl)pentanoate

Conditions
ConditionsYield
Stage #1: pilocarpine hydrochloride With sodium hydrogencarbonate In acetone at 20℃; for 0.0833333h;
Stage #2: (R)-1,2-dithiolane-3-pentanoic acid In acetone at 20℃; for 16h;
91.58%
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

copper dichloride

copper dichloride

dichloro-bis(κN-(+)-pilocarpine)copper(II)

dichloro-bis(κN-(+)-pilocarpine)copper(II)

Conditions
ConditionsYield
With Na2CO3 In chloroform; water; butan-1-ol organic ligand in water alkalinized with Na2CO3 to pH=9; extracted with CHCl3; removed in vacuo; dissolved in butanol; 0.5 equivalent of CuCl2 in butanol added; heated for a few minutes; sepd. by filtration; crystals grown from acetone; elem. anal.;14%
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

3-ethyl-4,5-dihydro-4-<(1-methyl-1H-imidazol-5-yl)methyl>-2(3H)-thiophenethione
117639-12-0

3-ethyl-4,5-dihydro-4-<(1-methyl-1H-imidazol-5-yl)methyl>-2(3H)-thiophenethione

Conditions
ConditionsYield
With Lawessons reagent In xylene at 135℃; for 7h;4.63 g
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

A

sodium isopilocarpate
101769-87-3

sodium isopilocarpate

B

sodium pilocarpate
92598-79-3

sodium pilocarpate

Conditions
ConditionsYield
With sodium hydroxide In water at 0 - 4℃; for 1h; Yield given;
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

A

isopilocarpine
531-35-1

isopilocarpine

B

Pilocarpinsaeure
28406-15-7

Pilocarpinsaeure

C

Isopilocarpinsaeure
34350-99-7

Isopilocarpinsaeure

Conditions
ConditionsYield
With potassium chloride In water for 1h; Kinetics; Thermodynamic data; Mechanism; Heating; var. pH-value, temp., times; epimerisation;
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

methanolic hydrochloric acid

methanolic hydrochloric acid

chloropilocarpinic acid methyl ester

chloropilocarpinic acid methyl ester

Conditions
ConditionsYield
Erhitzen auf Siedetemperatur;
Conditions
ConditionsYield
at 205 - 210℃;
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

benzylamine
100-46-9

benzylamine

A

cis-N-benzylpilolactam

cis-N-benzylpilolactam

B

trans-N-benzylpilolactam

trans-N-benzylpilolactam

Conditions
ConditionsYield
for 40h; Benzylation; Heating;
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

isopilocarpine
531-35-1

isopilocarpine

Conditions
ConditionsYield
Stage #1: pilocarpine hydrochloride With sodium hydroxide
Stage #2: With hydrogenchloride
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

Pilocarpinsaeure
28406-15-7

Pilocarpinsaeure

Conditions
ConditionsYield
With ammonium hydroxide at 90℃; for 2h;
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

Isopilocarpinsaeure
34350-99-7

Isopilocarpinsaeure

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: aq. NaOH
1.2: aq. HCl
2.1: aq. NH3 / 2 h / 90 °C
View Scheme
Multi-step reaction with 2 steps
1.1: aq. NH3 / 2 h / 90 °C
2.1: aq. NaOH
2.2: aq. HCl
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(3R,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)-methyl]-2-pyrrolidinone
137034-76-5

(3R,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)-methyl]-2-pyrrolidinone

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 40 h / Heating
2: Li; PrNH2; H2NCH2CH2NH2 / 2-methyl-propan-2-ol / 4 h / 0 °C
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid ethyl ester
96914-10-2

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 27 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid hexyl ester
96914-11-3

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid hexyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 36 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid butyl ester
92598-80-6

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid butyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 30 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid benzyl ester
92598-82-8

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid benzyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 35 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid phenethyl ester
92598-86-2

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid phenethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 22 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

pilocarpic acid 4-methylbenzyl ester
92598-93-1

pilocarpic acid 4-methylbenzyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 40 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 1-phenyl-ethyl ester
92598-81-7

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 1-phenyl-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 35 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 2-methyl-benzyl ester
92598-92-0

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 2-methyl-benzyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 35 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 4-chloro-benzyl ester
92598-89-5

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 4-chloro-benzyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 43 percent / dimethylformamide / Ambient temperature
View Scheme
pilocarpine hydrochloride
54-71-7

pilocarpine hydrochloride

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 4-tert-butyl-benzyl ester
92598-99-7

(2S,3R)-2-Ethyl-3-hydroxymethyl-4-(3-methyl-3H-imidazol-4-yl)-butyric acid 4-tert-butyl-benzyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NaOH / H2O / 1 h / 0 - 4 °C
2: 18 percent / dimethylformamide / Ambient temperature
View Scheme

54-71-7Relevant articles and documents

PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY

-

, (2012/05/04)

The invention relates to pharmaceutics, medicine, in particular to manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.

Synthesis of optically active lactones from L-aspartic acid and intermediates thereof

-

, (2008/06/13)

Optically active lactones are described, such as an intermediate lactone having the formula STR1 where R and R2 are each independently alkyl with 1 to 6 carbon atoms, cycloalkyl with 6 to 10 carbon atoms, aryl with 6 to 10 carbon atoms, or arylalkyl with 7 to 19 carbon atoms, R4 is H or C1-6 alkyl, and Ar is a homo- or heteroaromatic ring with 5 or 6 ring atoms being optionally substituted by C1-6 alkyl or alkoxy groups, halogen atoms, cyano or nitro groups. Such optically active, intermediate lactones are prepared from L-aspartic acid, and can be readily converted to (+)-pilocarpine and its analogues by hydrolysis, reduction, and hydrogenation, such as to an optically active lactone having the formula STR2 which is (+)-pilocarpine when R is ethyl, R4 is H, and Ar is 1-methylimidazol-5-yl.

Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent

-

, (2008/06/13)

A sustained-release polymeric hydrogel dosage form useful for topical, systemic or transdermal administration of a medicinal agent comprising a cross-linked, polymerized hydrophilic polymer, an amino acid polymer, a cross-linking agent, and an optional hydrophobic monomer and/or a chain regulator in conjunction with a lower alkyl (C1 -C4), polar solvent and said medicinal agent in a therapeutically effective amount.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 54-71-7